Stoke Therapeutics

STOK · NASDAQ

$26.61+$1.79 (+7.21%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.82

STOK analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 15 analysts

Average $47.94 (+80.2% upside)

Low: $35.35
Now: $26.61
High: $63.00

Upgrades and downgrades

The latest rating actions, newest first

STOK analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Aug 21, 2026	Initiates	Overweight	$40.00	57%
Guggenheim	Aug 4, 2026	Maintains	Buy	$60.00	49%
Wedbush	Aug 4, 2026	Maintains	Outperform	$38.00 → $40.00	40%
Canaccord Genuity	Aug 4, 2026	Maintains	Buy	$60.00 → $58.00	42%
Chardan Capital	Aug 4, 2026	Maintains	Buy	$35.00	38%
Goldman Sachs	Jul 13, 2026	Initiates	Buy	$44.00	0%
BTIG	May 11, 2026	Maintains	Buy	$39.00	30%
Canaccord Genuity	Mar 20, 2026	Maintains	Buy	$36.00 → $60.00	42%
BTIG	Mar 19, 2026	Maintains	Buy	$39.00	30%
Wedbush	Mar 18, 2026	Maintains	Outperform	$36.00 → $38.00	40%

The case for and against

Updated Sep 8, 2026

Bull case

Stoke Therapeutics is generating immense potential in the biotech industry with their innovative TANGO platform and drug candidates such as zorevunersen and STK-002. These drugs have shown promising results in preclinical and early clinical trials in treating genetic diseases, and the company's partnerships with other biotech companies further solidify their position in the market. With a strong cash position and a potential for disease modification, Stoke has the capability to address a broad unmet need in the genetic disease space.

Bear case

Stoke Therapeutics is facing potential challenges in successfully developing and commercializing its RNA medicine approach, with limited data from its early programs. Its financial results show a significant increase in expenses, with continued reliance on third-party data and the need for additional capital to become profitable. The company also faces risks related to potential patent disputes and the volatility of its stock price due to a significant stake held by Skorpios Trust. Adherence to appropriate pricing strategies will be crucial in ensuring market acceptance for its product candidates and maintaining adequate coverage and reimbursement.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.